OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
RGBP
Regen Biopharma, Inc.
0.08
-0.006
-6.98%
0.08 / 0.086 (1 x 1)
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
PR Newswire
SAN DIEGO, February 21, 2018
SAN DIEGO, February 21, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to it. The object of this structure-determination program is to shed light on how the small molecules bind to and modulate NR2F6 activity.
Determining the X-ray crystal structure of a protein and its ligand is a multi-step process:
- High levels of the protein are expressed.
- A saturated solution of protein is created in the presence of ligand. If the protein of interest has never been structurally determined before (as in the case of NR2F6), scores of different conditions must be tested. High levels of protein are needed in the first step, because ample protein is required to saturate a solution and to test many different conditions.
- Finally, if crystals form, their structural features are determined. This is done by exposing the crystals to a very high-power x-ray beam. The x-ray beam hits the protein and diffracts. The pattern of diffraction is used to determine the structure.
"We are making good progress in the crystallization phase of the process of x-ray structure determination. Crystals produced during the third step must be of high quality to be useable for structure determination," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"We are pleased this program continues to advance on time and are looking forward to having data that further de-risks our program," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
